Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16687397 | 0.82 | IDO1 (0.36) | TAAR1MAOBMPOSLC6A4IDO1 | |
| SCHEMBL29953243 | 0.82 | IDO1 (0.36) | TAAR1MAOBMPOSLC6A4IDO1 | |
| SCHEMBL24474343 | 0.78 | TAAR1 (0.36) | TAAR1MPOSLC6A4HTR2AIDO1 | |
| SCHEMBL146988 | 0.78 | CES2 (0.42) | — | |
| SCHEMBL28521385 | 0.76 | LIPG (0.33) | TAAR1MPO | |
| SCHEMBL23685407 | 0.76 | GABRA1 (0.46) | — | |
| SCHEMBL9939108 | 0.73 | LIPG (0.40) | TAAR1PNMTF11LOXL2 | |
| SCHEMBL214409 | 0.73 | TAAR1 (0.52) | TAAR1MAOBPNMTMPOSLC6A4 | |
| SCHEMBL28513719 | 0.73 | IDO1 (0.34) | MAOBIDO1 | |
| SCHEMBL14689847 | 0.72 | TAAR1 (0.46) | TAAR1MAOBPNMTIDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | TAAR1 4440/4885MAOB 2923/4885PNMT 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.